百诚医药
(301096)
| 流通市值：47.60亿 | | | 总市值：75.00亿 |
| 流通股本：6912.19万 | | | 总股本：1.09亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 215,702,841.54 | 1,017,448,123.5 | 713,806,299.44 | 423,862,084.23 |
| 营业收入 | 215,702,841.54 | 1,017,448,123.5 | 713,806,299.44 | 423,862,084.23 |
| 二、营业总成本 | 164,553,615.62 | 714,528,892.94 | 479,524,433.1 | 287,266,507.76 |
| 营业成本 | 68,611,172.02 | 350,737,208.85 | 233,294,848.44 | 141,743,437.07 |
| 税金及附加 | 2,433,835.17 | 5,703,689.63 | 3,214,454.5 | 1,220,749.26 |
| 销售费用 | 1,472,525.93 | 9,651,970.23 | 6,751,785.5 | 4,299,349.2 |
| 管理费用 | 28,047,860.43 | 128,625,740.02 | 99,131,994.35 | 61,255,473.2 |
| 研发费用 | 65,271,951.41 | 241,016,943 | 153,965,605.04 | 91,811,586.58 |
| 财务费用 | -1,283,729.34 | -21,206,658.79 | -16,834,254.73 | -13,064,087.55 |
| 其中:利息费用 | 3,434,450.84 | 7,109,891.6 | 4,423,330.79 | 2,478,978.45 |
| 其中:利息收入 | 4,761,962.54 | 28,483,543.86 | 21,428,464.19 | 15,707,102.34 |
| 加:投资收益 | 31,265.03 | -107,914.47 | 105,681.06 | 105,681.06 |
| 资产处置收益 | - | 780,714.74 | 958,058.51 | 968,781.22 |
| 资产减值损失(新) | -2,671,553.8 | -12,906,614.65 | -7,594,196.65 | -6,239,486.57 |
| 信用减值损失(新) | -1,899,293.6 | -9,859,313.92 | -3,602,523.01 | -3,058,146.25 |
| 其他收益 | 1,195,637.89 | 16,195,566.65 | 1,569,930.88 | 784,737.29 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 47,805,281.44 | 297,021,668.91 | 225,718,817.13 | 129,157,143.22 |
| 加:营业外收入 | 93,542.83 | 384,700.21 | 318,740.14 | 191,895.71 |
| 减:营业外支出 | 1,508.48 | 1,726,878.93 | 1,681,323.52 | 1,638,478.85 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 47,897,315.79 | 295,679,490.19 | 224,356,233.75 | 127,710,560.08 |
| 减:所得税费用 | -1,920,893.35 | 23,664,779.02 | 22,827,587.29 | 8,208,742.95 |
| 六、净利润 | 49,818,209.14 | 272,014,711.17 | 201,528,646.46 | 119,501,817.13 |
| 持续经营净利润 | 49,818,209.14 | 272,014,711.17 | 201,528,646.46 | 119,501,817.13 |
| 归属于母公司股东的净利润 | 49,818,209.14 | 271,966,149.52 | 201,487,597.66 | 119,460,768.33 |
| 少数股东损益 | - | 48,561.65 | 41,048.8 | 41,048.8 |
| (一)基本每股收益 | 0.46 | 2.51 | 1.86 | 1.1 |
| (二)稀释每股收益 | 0.46 | 2.51 | 1.86 | 1.1 |
| 八、其他综合收益 | -1,349.85 | -136,186.95 | -63,253.26 | -61,142.5 |
| 归属于母公司股东的其他综合收益 | -1,349.85 | -136,186.95 | -63,253.26 | -61,142.5 |
| 九、综合收益总额 | 49,816,859.29 | 271,878,524.22 | 201,465,393.2 | 119,440,674.63 |
| 归属于母公司股东的综合收益总额 | 49,816,859.29 | 271,829,962.57 | 201,424,344.4 | 119,399,625.83 |
| 归属于少数股东的综合收益总额 | - | 48,561.65 | 41,048.8 | 41,048.8 |
| 公告日期 | 2024-04-23 | 2024-04-23 | 2023-10-26 | 2023-08-10 |
| 审计意见(境内) | | 标准无保留意见 | | |